Recapitulating aspects of human organ functions using in-vitro (e.g., plates, transwells, etc.), in-vivo (e.g., mouse, rat, etc.), or ex-vivo (e.g., organ chips, 3D systems, etc.) organ models are of paramount importance for precision medicine and drug discovery. It will allow us to identify potential side effects and test the effectiveness of therapeutic approaches early in their design phase and will inform the development of accurate disease models. Developing mathematical methods to reliably compare the "distance/similarity" of organ models from/to the real human organ they represent is an understudied problem with important applications in biomedicine and tissue engineering. Results: We introduce the Transctiptomic Signature Distance, TSD, an information-theoretic distance for assessing the transcriptomic similarity of two tissue samples, or two groups of tissue samples. In developing TSD, we are leveraging next-generation sequencing data and information retrieved from well-curated databases providing signature gene sets characteristic for human organs. We present the justification and mathematical development of the new distance and demonstrate its effectiveness in different scenarios of practical importance using several publicly available RNA-seq datasets.
Introduction
Assessing the transcriptomic distance of biological samples (e.g., organ tissues, cells of different types, etc.) is essential for understanding their functional differences and recognizing disease states (Aibar et al. (2016) ; Crow et al. (2019) ; Mohammed et al. (2019) ; McDonough et al. (2019) ). Recently, significant efforts have been invested towards characterizing organ tissues (e.g., liver, kidney, intestine, etc.) of different species (e.g., human, mouse, rat, etc.) at various states (e.g., healthy, diseased, etc.) (Uhlen et al. (2015 (Uhlen et al. ( , 2017 ; Yu et al. (2015) ; Keen et al. (2015) ; Mele et al. (2015) ; Suntsova et al. (2019) ; Sollner et al. (2017) ) using RNA-sequencing, a mature technology for quantifying gene transcripts in biological samples. A notable effort is the Human Protein Atlas (HPA) project (Uhlen et al. (2015) ), a Swedish-based program providing, among others, gene expression signatures for 37 healthy human organ tissues. In particular, the HPA provides for every tissue type a set of genes exhibiting significantly elevated expressions compared to the other organ tissue types. It is widely accepted that these gene sets form a "transcriptomic signature" of the specific organ, and their expression patterns characterize the tissue's underlying biological processes.
Recent advancements in bioengineering and biotechnology have enabled the development of cell-cultured based organ models that recapitulate critical functions of human organs (e.g., liver, intestine, brain. etc.) (Jang et al. (2019) ; Kasendra et al. (2019) ). The emerge of such ex-vivo human organ models generated in turn the need for new mathematical tools for determining their "similarity" to the actual human organ they represent. Such tools will not only help us understand the model capabilities and limitations but also reveal aspects we can improve in their design to optimize their physiological relevance and increase their value for precision medicine. Next-generation sequencing data (e.g., RNA-seq) is already utilized to determine the distance between organ tissue samples (Mele et al. (2015) ; Suntsova et al. (2019) ; Sollner et al. (2017) ; Sudmant et al. (2015) ) in conjunction with classical mathematical tools such as the Euclidean distance, or dimensionality reduction techniques (e.g., Principal Component Analysis, Linear Discriminant Analysis, Uniform Manifold Approximation and Projection, etc.). However, all these methods exhibit significant limitations due to sensitivity to noisy measurements and outliers, inability to capture non-linear relations, etc. (Pereira et al. (2009) ; Li et al. (2016) ). In this work, we introduce a new distance, called Transcriptomic Signature Distance (TSD), that was inspired from the field of information retrieval, addresses the problem of tissue sample comparisons in the well-established framework of information theory, and circumvents the above-mentioned weaknesses of more classical approaches.
Text similarity is a well-studied problem in information retrieval (Pradhan et al. (2015) ; Nagwani et al. (2015) ). Over the years, many techniques have been proposed to measure the distance/similarity of documents based on features such as word frequencies, word patterns in sentences, etc. They process vector representations of documents and assume that documents with similar content exhibit similar feature patterns. RNA sequencing, on the other hand, allows us to read the transcriptome (i.e., read the stories) of tissues. These transcriptome "stories" are written using a four nucleotide bases alphabet, which is applied to construct words (i.e., the genes). Based on this analogy, the transcriptome of homologous tissues should "tell" similar stories, and therefore the set of words (i.e., genes), their relative frequencies of appearance, and rankings in the stories are expected to be similar as well.
Our method exploits well-curated databases (e.g., HPA, GTExPortal, etc.) to retrieve genes that are considered transcriptomic signatures of the compared organ tissues (Yu et al. (2015) ; Lonsdale et al. (2013) ). These are sizeable gene sets that can adequately characterize the "identity" of organ tissues. Using them as the basis in comparing tissue samples allows us to significantly reduce the effects of sequencing "background noise" and donor-to-donor variability in the analysis. Moreover, making use of information theory and advanced statistical methods, TSD can capture the distance/similarity between any two arbitrary organ tissue samples, or between two tissue samples that are known to belong to two different classes (sample groups, e.g., different organs, organ models etc.). In the latter case, TSD considers, in a principled manner, the intraclass variabilities and incorporates them into the distance estimation. The proposed distance space is determined using the expressions probability distribution of the signature genes as well as their rankings profile in transcriptomes of the two tissues. We explain the advantages of the proposed distance and experimentally validate its ability to resolve transcriptomic distances between organ tissues in many practical situations of interest.
The rest of the paper is organized as follows: In Section 2, we present the development of TSD and justify why it can better capture the actual transcriptomic distance between two tissues. In Section 3, we present and discuss extensive experimental validation results in different scenarios of practical importance. Finally, we summarize our findings in Section 4.
Methods
In this section, we present TSD a new method to measure the transcriptomic distance between organ tissue samples. TSD requires as input the gene expression levels (e.g., hit-counts, CPM, TPM, FPKM, etc.) of two tissue samples (or two sets of tissue samples) where one tissue sample is assumed to be the "reference" (i.e., gold standard) from which we want to measure the distance of the other tissue sample.
Preliminaries
We use lowercase letters to denote scalars, bold lowercase (uppercase) letters for vectors (matrices), and bold uppercase calligraphic letters for sets. Letṡ = [ġ 1 ,ġ 2 , ...,ġ N ] ands = [g 1 ,g 2 , ...,g N ] be two vectors storing the expression levels of N genes after applying RNAsequencing on tissue samplesṫ andẗ respectively. For presentation purposes we assume thatṫ is our "reference" tissue sample andẗ the sample of tissue that we want to measure its distance fromṫ. From the Human Protein Atlas database we retrieve the M ≤ N genes that characterize the reference organ where tissueṫ was sampled from and are a subset of genes {g 1 , g 2 , ..., g N }. Then, usingṡ ands we form the corresponding Atlas signature vectorsṡ
. For each Atlas signature vector, we estimate the corresponding discrete probability distributionṗ
The probabilities of each Atlas gene are calculated using:
(1) In addition, we form the vectorsρ
..,r A M ] containing the expression level rankings of the Atlas genes of the reference tissue (ṫ) in the full transcriptome gene expression vectorsṡ ands. Note that 1 ≤ r A i ≤ N . In Section 2.2, we present the "simple" version of the TSD that measures the transcriptomic distance between any two organ tissue samples. In Section 2.3 we present the development of the more general version, the so called weighted-TSD (wTSD), used to estimate the distance between two samples knowing that they belong to two different classes (tissue sets) and taking into account the intra class variabilities.
The Transcriptomic Signature Distance
The proposed TSD measures the transcriptomic distance between a tissue sampleẗ from a "reference" tissue sampleṫ as the average of the Jensen-Shannon Divergence (JSD) (Section 2.2.1) and the Rankings Correlation Distance (RCD) (Section 2.2.2). We present below the two distances and their limitations when used in isolation that justifies their combined use in assessing tissue distances.
The Jensen Shannon Divergence
JSD is popular for measuring the similarity between two probability distributions and is related to Shannon's entropy, Kullback-Leibler Divergence (KLD) and mutual information (Fuglede et al. (2004) ). JSD calculates the divergence (distance) between the probability distributionṡ p A andp A using the following equation:
is the Shannon's entropy function (Jianhua et al. (1991) ). Unlike KLD, the square root of the JSD (SR-JSD) satisfies all the basic properties of a "true" metric, such as symmetry, non-negativity, triangle inequality and identity of indiscernibles. Given that we use the base-2 logarithm for calculating the Shannon's entropy (see equation (2)), the SR-JSD is bounded in the interval [0, 1] where 0(1) corresponds to minimum (maximum) distance. SR-JSD uses the probability distributions of the reference Atlas genes to measure the distance between the two samples and therefore it does not take into account the expression levels of these genes in the whole transcriptome which is very important for the development of an accurate tissue distance metric. The following example demonstrates this limitation. Figure 1a shows the whole gene expression profiles (N = 20 w.l.o.g) of two organ tissuesṫ andẗ. Let's assume that {g A 1 , ..., g A 10 } are the [8, 7, 5, 3, 1, 2, 4, 6, 9, 10] and ρ A = [16, 13, 9, 5, 3, 4, 7, 11, 17, 18] respectively differ significantly which captures the tissue differences in this case.
reference Atlas genes (M = 10) that characterize tissueṫ. Using their expressions in both tissues (see Figure 1b ), we form vectorsṡ A and s A and calculate the corresponding probability distributionsṗ A andp A (Figure 1c ). Since both tissues in this example {ṫ,ẗ} exhibit proportional gene expression for the Atlas genes, this results to identical probability distributions ( Figure 1c ) and therefore SR-JSD(ṗ A ,p A ) = 0, suggesting thatṫ andẗ are transctiptomically very close. However, as we can see in Figure 1a this is apparently not the case, which shows that using SR-JSD alone may fail to capture tissues transcriptomic distance. To deal with this limitation, we propose to also employ in TSD the correlation coefficient of the rankings of the Atlas genes in the whole transcriptome that can correct this situation (see Figures 1d and 1e ) .
The Rankings Correlation Coefficient
The Rankings Correlation Coefficient (RCC) is defined as the Pearson's correlation of the Atlas gene ranking vectors, namelyρ A andρ A , in the whole transcriptome. It is calculated based on the formula:
wherer A andr A are the corresponding mean rankings. The range of RCC is [-1, 1] where 1(-1) implies perfect linear relation between the compared ranking vectors. Applying equation (3) to the Atlas ranking vectors provides us information about the linear relation of the reference Atlas genes in the whole transcriptome of the two tissues based on their expressions. Figures  1d and 1e demonstrate the ranking profile difference of the Atlas genes in the transcriptomes ofṫ andẗ respectively. This difference can successfully capture the tissues dissimilarity when SR-JSD may fail to do so as in the example of Figure 1 .
Transcriptomic Signature Distance
The example presented in Figure 1 demonstrates the limitation of the SR-JSD to measure with accuracy the transcriptomic signature distance between two tissues. A similar example that demonstrates a corresponding limitation when RCC is used alone, is provided in Figure 2 . In this example, tissuesṫ andẗ have identical reference Atlas gene rankings in the corresponding transcriptomes ( Figure 2d and 2e) but different probability distributions ( Figure 2c ). In this case, using RCC alone would suggest that the transcriptomic signatures of the tissues are identical which is not the case. To address the limitations introduced when using either SR-JSD or RCC independently, we introduce the Transcriptomic Signature Distance (TSD) which combines them:
where RCD = 1 − ReLU (RCC) is the Rankings Correlation Distance. ReLU is the Rectified Linear Unit activation function defined as: ReLU (x) = x, when x > 0 and zero otherwise. For the calculation of the RCD we assume that if two ranking vectors have RCC < 0 (i.e. are anti-correlated) then their Rankings Correlation Distance is maximal (i.e. 1). Note that TSD is bounded in the interval [0, 1] where 0(1) corresponds to minimum (maximum) distance.
Transcriptomic Signature Distance of samples belonging to two different tissue sets
In Section 2.2 we presented TSD that can measure the distance between any two tissue samplesṫ andẗ without considering their classification. Here we study the case where we want to measure the distance between two samples knowing that they belong to two different tissue sets (e.g., ex-vivo organ model samples vs. human organ samples). We propose a modified version [2, 8, 3, 1, 11, 13, 10, 18, 15, 19] of the Atlas genes in the transcriptome are identical for both tissues, which results to RCC = 1. In this example, using the RCC of the Atlas genes alone fails to capture the transcriptomic differences of the two tissues. of the TSD, which takes into account the gene expression variability of the samples within the corresponding tissue sets and provides statistically robust and accurate estimations of their transcriptomic signature distances.
Let's assume that we have two sets of tissue samplesṪ = {ṫ 1 ,ṫ 2 , ...,ṫ V } andT = {ẗ 1 ,ẗ 2 , ...,ẗ U }. Similarly to the notation used in Section 2.1,T corresponds to the set of tissue samples that we want to compare to the reference setṪ . For each tissue samplė t i ∈Ṫ , where i = {1, 2, ..., V }, andẗ j ∈T , where j = {1, 2, ..., U }, we form the: (i) gene expression profile vectorsṡ i ands j ; (ii) the Atlas signature vectorsṡ A i ands A j ; (iii) the discrete probability distributions of the Atlas genesṗ
..,P A jM ]; and (iv) the matrices {Π,Π} that summarize the Atlas gene probability distributions of the corresponding samples.
The weighted Jensen-Shannon Divergence
InΠ andΠ, we assume that the probabilities of appearance of each Atlas gene (e.g. k th gene) across tissue samples (i.e. rows of matrices), were generated by a normal distribution (e.g. N (μ k ,σ 2 k ) and N (μ k ,σ 2 k )) with parameters:μ
Using this assumption, for each tissue {ṫ i ,ẗ j }, the likelihood of appearance of the k th Atlas gene can be calculated as:
The larger the F (Ṗ A ik ;μ k ,σ 2 k ) (F (P A jk ;μ k ,σ 2 k )) the more "confident" we are about the likelihood of appearance of the k th Atlas gene in the set of samplesṪ (T ). We quantify our "confidence" as:
where to avoid negative "confidence" values we added "1" before taking the logarithm of the likelihoods. To incorporate our "confidence" about the likelihood of appearance of the Atlas genes in the JSD we utilize a weighted version of the Shannon's entropy H (Jianhua et al. (1991) ):
are the corresponding weighted discrete probability distributions that describe the probabilities of the reference Atlas genes to appear in the transcriptome of the corresponding tissues. The weighted probabilities are calculated as:
(10) To calculate the wJSD (see equation (9)), we need also to determine the weightsẇ i andẅ j of the corresponding probability distributionsṗ A i andp A j . Next, we present a novel method that quantifies our "confidence" on how well the tissue samples {ṫ i ,ẗ j } "represent" their corresponding tissue sets {Ṫ ,T }, and appropriately adjust the weight values {ẇ i ,ẅ j }.
For each tissue set {Ṫ ,T }, we form the matricesΨ andΨ where each of their rows (i.e.ψ A i andψ A j ) correspond to the standardized versions (e.g. z-scores) of the Atlas signature vectors (ṡ A i ,s A j ) of the corresponding tissue samples.
We assume that each standardized reference Atlas signature vector (e.g.ψ A i andψ A j ) is a random realization of a multivariate normal distribution (e.g. N (0,Σ) and N (0,Σ)). To estimate the covariance matrices {Σ,Σ} of these distributions we apply the Graphical Lasso (GL) algorithm to the corresponding data matrices {Ψ,Ψ}. GL is a computationally efficient algorithm which has been extensively used to identify gene-gene interaction networks from RNA-seq datasets (Friedman et al. (2008) ). Its main advantage, is its ability to estimate the precision matrix (i.e. Ω = Σ −1 ) even in cases where the number of samples is far less than the number of variables (n<<p) which holds for transcriptomic datasets (i.e. number of samples << number of genes). In such cases, other covariance estimation methods, such as Maximum Likelihood Estimation, fail since the sample (or empirical) covariance matrix S is rank deficient. GL addresses this limitation using the assumption that precision matrix Ω = Σ −1 is sparse (i.e. the graph structure of the variables' interactions is sparse). To estimate the precision matrix Ω, GL efficiently solves the following optimization problem:
where ||.|| 1 is the L 1 -norm (i.e. the sum of the absolute values of the elements of Ω); det(Ω) is the determinant of Ω; λ is the sparsity parameter that controls the density (i.e. the number of edges) of the graphical model; and S the M × M sample covariance matrix calculated as S = Ψ T Ψ.
To optimally choose the value of λ we use the StARS method (Liu et al. (2010) ) which is stability-based approach for selecting the regularization parameter in high dimensional graphical models. Using the estimated covariance matrices of the multivariate normal distributions N (0,Σ) and N (0,Σ) we calculate the likelihood of the tissue samplesṫ i andẗ j to belong to the corresponding distributions as:
The likelihoods Z(ψ A i ; 0,Σ) and Z(ψ A j ; 0,Σ), provide information on how "confident" we are that the tissue samplesṫ i andẗ j are "good" representatives of the corresponding tissue set {Ṫ ,T }. Using this information we calculate the weights {ẇ i ,ẅ j } as:
where V and U are the number of samples in tissue setsṪ andT respectively. Note thatẇ i +ẇ j = 1. Note that for the calculation of the weight we also consider the sample sizes of the corresponding tissue sets. More specifically, the larger the sample size the larger the weight we assign to the corresponding distribution. This can be justified if we consider that larger the sample sizes provide more confidence about the accuracy of the estimated parameters (i.e. covariance matrix) of the multivariate normal distribution.
The weighted Rankings Correlation Coefficient
The second term of the TSD (see equation (4)) is the rankings correlation distance (RCD) between the reference Atlas genes ranking vectors {ρ A ,ρ A } of the compared tissuesṫ,ẗ. For the case where we have sets of tissue samples (i.e.Ṫ andT ) we use weighted Rankings Correlation Coefficient (wRCC) which can be calculated as:
βq (15) are the corresponding weighted means of the rankings of the Atlas genes. in equation (15) βq, where q = {1, ..., M }, are the weights which assign different "confidence" to the corresponding rankings of the M Atlas genes. To calculate the values of these weights, we propose the following method.
Using the ranking vectors {ρ A i ,ρ A j } of the Atlas genes of the tissue samples that contained in each set (i.e.Ṫ andT ) we form the following matrices:
Each row of matricesṘ andR contains the rankings of the expressions of the Atlas genes in the transcriptome of the corresponding tissue sample, and each column includes the rankings of the expressions of a specific Atlas gene across the tissue samples of the corresponding set.
In matricesṘ andR, we assume that the rankings of each Atlas gene (e.g. k th gene) across tissues, were generated by a normal distribution (e.g. N (γ k ,δ 2 k ) and N (γ k ,δ 2 k )) with parameters:
Using this assumption, the likelihood about the rankings of the k th Atlas gene can be calculated as:
The larger the Ξ(ṙ A ik ;γ k ,δ 2 k ) (Ξ(r A jk ;γ k ,δ 2 k )) the more "confident" we are about the rankingṙ A ik (r A jk ) of the k th Atlas gene, We quantify our "confidence" as:τ A ik = log 10 (Ξ(ṙ A ik ;γ k ,δ 2 k ) + 1)
To avoid negative "confidence" values we added "1" before taking the logarithm of the likelihoods. Using theτ A ik andτ A jk we calculate the importance weight of the k th Atlas gene as:
By applying these weights to equation (15) we can calculate the wRCC which also takes values in range [-1, 1].
The weighted Transcriptomic Signature Distance
After calculating wJSD and wRCC we can calculate the weighted version of the transcriptomic signature distance (wTSD) as:
where wRCD = 1 − ReLU (wRCC)} is the weighted Rankings Correlation Distance. For the calculation of the wRCD we assume that if two vectors have wRCC < 0 (i.e. anti-correlated) then their Rankings Correlation Distance is maximum (i.e. 1). Similar to the TSD (see equation (4)), wTSD takes its values in [0, 1].
Results and Discussion
We present here extensive results generated using publicly available RNA-seq datasets demonstrating the validity and value of the proposed Transcriptomic Signature Distance (i) for measuring the distance between different organ tissues, (ii) for assessing the distance between healthy and diseased organ tissues, and (iii) for evaluating the similarity of organ models (e.g., organoids, animals, etc.) to the corresponding human organ.
3.1 Using wTSD with real data to assess distance of human organ tissues
In Section 2.2 we used two hypothetical scenarios to illustrate that using SR-JSD or RCC alone may fail to adequately capture the transcriptomic differences of tissue samples. In this section, we use real data to show this ineffectiveness and justify the advantages of the proposed wTSD as a higher resolution method. For this purpose, we used the publicly available dataset in GEO GSE120795, also presented in Suntsova et al. (2019) , a comprehensive gene expression database of normal human tissues based on uniformly screened RNA-seq data. This database includes 142 tissue samples taken from 20 organs of healthy human donors of different ages, collected no later than 36 hours after death. The Human Protein Atlas (HPA) includes information for only 13 out of the 20 organs in the database, and these were used in our analysis. As we can see in Table S1 in Supplementary Material the number of samples as well as the number of signature genes identified by the HPA project for each one of the 13 organs used vary considerably. The wTSD distance is designed to deal with this kind of situations in a principled manner. The Heatmaps of Figure 3 depict the mean inter/intra-organ distances. Each row corresponds to a specific organ being used as reference whose HPA signature genes were utilized to estimate the distances of the other organs (columns) from it. As expected, the mean intra-organ tissue sample distances (main diagonal elements) are smaller than the corresponding inter-organ distances (off-diagonal elements of the same row).
If we examine carefully corresponding rows in Figures 3a and  3b we see that in many cases there is no correlation between the corresponding SR-wJSD and wRCD values, indicating that these two pieces of information capture different aspects of transcriptome dissimilarities. To better illustrate this fact, Figures 4a-4b and 4c -4d depict the distances of organs from Lung and Kidney (references) respectively in a 2D-space where SR-wJSD and wRCD are used as coordinates. In these plots, each organ's name label is centered at the mean value of the corresponding pairwise tissue sample distances (SR-wJSD and wRCD) from the reference organ. In the zoomed-in version of Figure 4b we see that the {Liver, Brain} and {Small Intestine, Thyroid} pairs have almost equal wRCDs but different SR-wJSDs coordinate values. On the other hand, in the zoomedin Figure 4d , {Thyroid, Esophagus}, {Pancreas, Small Intestine} as well as {Bladder and Prostate} pairs have almost equal SR-wJSDs but different wRCDs coordinate values. Based on these observations it is clear that the proposed new distance, wTSD, which combines the SR-wJSDs and wRCDs information while also taking into account the intra-class tissue samples variability of every organ (see Section 2), provides a higher resolution picture of the reality.
Using wTSD to assess tissue distance of disease subtypes and progression stages
In this section, we present results demonstrating that TSD can be used to resolve transcriptomic distance of normal tissues from tissues of disease subtypes as well as tissues of different disease progression stages. For this purpose, we are using publicly available RNA-seq datasets characterizing two different diseases: idiopathic pulmonary fibrosis and liver cancer. (Kim et al. (2006) ; Lederer et al. (2018) ). The RNA-seq dataset of this study, available in NCBI's Gene Expression Omnibus (GEO GSE124685), consists of 84 samples classified in the following four categories: (i) Controls (n=35), (ii) IPF Early (n=19), (iii) IPF Moderate (n=15) and (iv) IPF Severe (n=15). The samples' categorization was made based on the extent of lung fibrosis, assessed using microCT quantitative imaging and tissue histology (McDonough et al. (2019) ). Using this dataset and the information of the 239 genes which, according to HPA, can be considered as the transcriptomic signature of the healthy human lung (see Table S1 ), we calculated the transcriptomic distances (SR-wJSD, wRCD and wTSD) of all pairs of tissue samples, one sample belonging in the Controls (reference) group and the other in the diseased groups. Figure 5a shows the transcriptomic distances (SR-wJSD and wRCD) of the different IPF progression stages from the healthy lung tissues. The label of each IPF progression stage name is centered at the coordinates of the mean value of the pairwise distances of samples in the corresponding IPF progression group and Control group samples (all pair combinations considered). Figure 5b shows boxplots of the corresponding distributions of the pairwise wTSD distances. The results indicate that as the severity of IPF increases, the corresponding transcriptomic signature distance from the Control class also increases. This fact demonstrates the interpretability of the proposed distance. Table S2 in Supplementary Material summarizes the results of the two-sample t-test between the corresponding distributions of the pairwise wTSD distances (presented in Figure 5b ). The decision of the test is equal to 1 (h=1) if the test rejects the null hypothesis (that the groups of the distances have equal means and equal but unknown variances) at the 1% significance level. Table S2 results clearly show that wTSD can successfully identify the different IPF progression stages based on the HPA lung signature genes. Moreover, the wTSD differences are statistically significant for all comparisons between (i) the Control and IPF stages, and (ii) different IPF stages, a fact that demonstrates the ability of wTSD to capture the transcriptomic differences of the corresponding categories.
Using TSD with human liver cancer dataset
In a recent study Broutier et al. (2017) , human primary liver cancer-derived organoids were employed to recapitulate the pathophysiology of human liver tumors. From the provided RNA-seq dataset (GEO GSE84073), we extracted samples for healthy human liver tissue (Controls) and different human liver tumor subtypes, in particular: Hepato-Cellular Carcinoma (HCC), Cholangio-Carcinoma (CC) and combined HCC/CC (CHC). The number of tissue samples in each group was relatively small: (i) Controls (n=4), (ii) HCC (n=3), (iii) CC (n=4) and (iv) CHC (n=3). We also used for every sample the expression information of the 936 genes, which, according to HPA, form a transcriptomic signature of the healthy human liver (see Table S1 ). Next, using as reference organ the healthy human liver, we computed the corresponding pairwise distances (SR-JSD, RCD and TSD) between its samples and samples in the different cancer subtype groups. We remark here that due to the limited number of samples in the cancer groups, we decided to use the simple version (not weighted) of the TSD. Figure 6a shows the transcriptomic distances (SR-JSD and RCD) of the different cancer subtypes from the healthy liver. Each cancer subtype's name label is centered at the coordinates of the mean value of the pairwise distances between samples in the corresponding cancer group and Control samples. Figure 6b shows boxplots of the distributions of these pairwise TSD distances. These results demonstrate the ability of TSD to represent the distance difference of controls from the tumor subtypes. It is interesting to remark that the distance of the CHC group (tumor tissue, which is a combination of HCC and CC) from the Controls is in-between the corresponding distances of the HCC and CC, a fact that conforms with our human intuition. Moreover, Table S3 in the Supplementary Material summarizes the results of the two-sample t-test between the corresponding distributions of the pairwise TSD distances (presented in Figure 6b ). In Table S3 , the decision of the test is equal to 1 (h=1) if the test rejects the null hypothesis at the 5% significance level. The results show that all comparisons except one (Control vs. HCC) have significantly different TSD distances, which indicates the ability of TSD to identify the transcriptomic differences of the corresponding groups.
Assessing distance of human organs from different organ models
In this section, we show that the proposed transcriptomic signature distance can be used to assess the "physiological relevance" of different organ models to a human organ based on RNA-seq data. Specifically, we computed the transcriptomic signature distance of: (i) mus musculus (mouse) organs, (ii) rattus norvegicus (rat) organs, and (iii) human-derived organoids from the human liver and kidney used as reference organs. We obtained the RNA-seq data for the healthy human organ tissues from the publicly available database developed by Suntsova et al. (2019) (described in Section 3.1). The number of available samples for each healthy human organ is provided in Table S1 . For mouse and rat, we obtained RNAseq data from the database developed by Sollner et al. (2017) . For both species, the number of available samples per organ was equal to 3. Finally, we retrieved RNA-seq data for healthy human liver and kidney derived organoids from the publicly available datasets (GSE84073 and GSE99582) presented in Broutier et al. (2017) and Phipson et al. (2017) respectively. The number of samples of the healthy liver and kidney organoids was 6 and 3, respectively. To compare the transcriptomic signatures between the different species, we associated the mouse and rat genes to human homologous genes using the R-package biomart (Smedley et al. (2015) ). Due to the limited number of samples (n = 3) in some of the categories under comparison, we used the "simple" version of TSD (not weighted). Figures 7a and 8a show, for the liver and kidney datasets respectively, the pairwise distances (SR-JSD and RCD) of organ model samples (mouse, rat, organoids) from healthy human organ tissue samples. In both Figures, a circle depicts the distance of a model tissue sample (represented by color black, blue, red) to a control sample. On the other hand green circles are used for pairwise distances between samples of the control group. The boxplots in Figures 7b and 8b summarize the distributions of these pairwise distances. The results indicate that the liver tissue samples 
